The Global Alliance for TB Drug Development

Tweet this page
<
2016
2017
2018
2019
2020
2021
2022
2023
2024
>
Registration as it was on 12 Mar 2024
How to read and use this data card.
Download this datacard

Overview

Since 20 September 2021 self-declared 'non-commercial organisations' are no longer required to provide a lobby budget. See above timeline for this registrant's historical lobby budget.

Lobbying Costs

None declared

Financial year: Jan 2022 - Dec 2022

Lobbyists (Full time equivalent)

0.8 Fte (5)

Lobbyists with EP accreditation

0

High-level Commission meetings

3

Lobbying Costs over the years

  • Info

    The Global Alliance for TB Drug Development   (TB Alliance)

    EU Transparency Register

    636752920377-18 First registered on 20 Jan 2016

    Goals / Remit

    TB Alliance is a not-for-profit organization dedicated to the discovery, development and delivery of better, faster-acting and affordable tuberculosis drugs that are available to those who need them.

    Main EU files targeted

    EU legislative proposal: European Health Emergency Preparedness and Response Authority (HERA) – meetings with European Commission officials; Horizon Europe, European and Developing Countries Clinical Trials Partnership (EDCTP), and EU initiatives connected to research and innovation (R&I) – meetings with European Commission officials; EU Global Health Strategy – meetings with European Commission officials; EU Pharmaceutical Package – contribution to consultation and meetings with European Commission officials

    Address

    Head Office
    80 Pine Street 20th floor
    New York 10005
    UNITED STATES
    EU Office
    80 Pine Street 20th floor
    New York 10005
    UNITED STATES

    Website

  • People

    Total lobbyists declared

    5

    Employment timeLobbyists
    25%2
    10%3

    Lobbyists (Full time equivalent)

    0.8

    Lobbyists with EP accreditation

    All Lobbyists with EP accreditation over time

    0 accreditations were / are live (in bold) for the selected state of 16 Jul 2024

    Name Start date End Date
    Willo BROCK 30 Aug 2019 29 Aug 2020
    Ms Erin MORTON 24 Feb 2018 23 Feb 2019
    Willo BROCK 20 Jan 2018 19 Jan 2019

    Complementary Information

    Number of persons includes 2 staff/employees and 3 consultants.

    Person in charge of EU relations

    Data not provided by Register Secretariat due to GDPR

    Person with legal responsibility

    Data not provided by Register Secretariat due to GDPR

  • Categories

    Category

    Non-governmental organisations, platforms and networks and similar

  • Networking

    Affiliation

    DSW - https://www.dsw.org/en/eu/

    AMR Stakeholder Network - https://epha.org/amr-stakeholder-network/

    Member organisations

    None declared

  • Financial Data

    Interests represented

    Does not represent commercial interests

    Closed financial year

    Jan 2022 - Dec 2022

    Lobbying costs for closed financial year

    Since 20 September 2021 self-declared 'non-commercial organisations' are no longer required to provide a lobby budget. See above timeline for this registrant's historical lobby budget.

    Total organisational budget in closed year

    55,774,420€

    Major funding types in closed year

    Grants

    Major contributions in closed year

    TypeNameAmount
    Contribution Bill and Melinda Gates Foundation 18,213,779€
    Contribution US NIH 5,994,348€
    Contribution UK FCDO 12,754,657€
    Contribution German BMBF 6,201,129€

    Other financial info

    TB Alliance is part of a consortium - UNITE4TB being funded under IMI/IHI AMR Accelerator mechanism.

  • EU Structures

    Groups (European Commission)

    none

    Groups (European Parliament)

    N/A

    Communication activities

    We participated in regular meetings with HERA, EDCTP3 and European Commission officials regarding TB Alliance Research and Innovation activities, and actively engaged in communications related to ongoing Commission policies related to EDCTP3 initiatives, EU Global Health Strategy, the EU Pharmaceutical Package and the possibility for the introduction of a novel Priority Review Voucher (PRV) type mechanism to encourage R&I investments in neglected disease research. Furthermore, we highlighted the contributions of the Commission and its various initiatives to support the work of global medical R&I in the context of the "Keeping the Promise: Product Development Partnerships' Role in the New Age of Health Research and Product Development" Report that we help draft and distribute.

    Other activities

    None declared

  • Meetings

    Meetings

    3 meetings found. Download meetings

    The list below only covers meetings held since November 2014 with commissioners, their cabinet members or directors-general at the European Commission; other lobby meetings with lower-level staff may have taken place, but the European Commission doesn't proactively publish information about these meetings. For more information about which commissioner is responsible for which portfolio, check out this link: https://commissioners.ec.europa.eu/index_en All information below comes from European Commission web pages.

    1 July 2024: We have noted that some meetings are appearing in duplicate, ie. some meetings seem to be listed twice. This seems to be because the Commission changes some element of a meeting data after the meeting has first been listed, which causes LobbyFacts to register it as a new meeting. We are investigating further.

    • Date 14 Oct 2022 Location Brussels
      Subject Global Gateway Strategy and Global Health Strategy
      Cabinet Cabinet of Commissioner Jutta Urpilainen
      Portfolio International Partnerships
      Attending
      • Renaud Savignat (Cabinet member)
    • Date 10 Oct 2018 Location Brussels
      Subject Global Health in Horizon Europe
      Cabinet Cabinet of Commissioner Carlos Moedas
      Portfolio Research, Science and Innovation
      Attending
      • Giulia Del Brenna (Cabinet member)
    • Date 25 Jan 2018 Location Brussels
      Subject EU action to help reduce TB
      Cabinet Cabinet of Commissioner Vytenis Andriukaitis
      Portfolio Health &amp; Food Safety
      Attending
      • Paula Duarte Gaspar (Cabinet member)
      • Vytenis Andriukaitis (Commissioner)
      Other Lobbyists
Download this datacard